翰宇药业(300199) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥167,212,356.18, a decrease of 6.36% compared to ¥178,572,479.97 in the same period last year[5] - The net profit attributable to shareholders was -¥57,654,813.97, representing a decline of 345.70% from ¥23,465,958.26 in Q1 2021[5] - The basic and diluted earnings per share were both -¥0.06, a drop of 300.00% from ¥0.03 in the same quarter last year[5] - Total operating revenue for the first quarter was CNY 167,212,356.18, a decrease of 6.5% from CNY 178,572,479.97 in the previous period[38] - Net profit for the period was a loss of CNY 58,377,053.71, compared to a profit of CNY 23,527,246.35 in the previous year[41] - The total comprehensive income attributable to the parent company was -58,061,508.86 CNY, compared to 24,834,756.08 CNY in the previous period[44] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 70.59%, amounting to ¥20,715,953.56 compared to ¥70,450,145.87 in the previous year[5] - Cash inflow from operating activities was 195,065,288.49 CNY, down from 201,372,687.13 CNY in the previous period[46] - Cash and cash equivalents at the end of the period totaled 108,536,391.98 CNY, compared to 653,813,006.77 CNY at the end of the previous period[53] - The company reported a cash inflow from financing activities of 23,073,485.61 CNY, down from 1,022,260,000.00 CNY in the previous period[53] - The company paid 12,478,692.05 CNY in debt repayments during the period, compared to 747,079,782.98 CNY in the previous period[53] - The company's cash and cash equivalents were not specified, but the overall financial position indicates a tightening of liquidity[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,778,314,755.91, down 3.28% from ¥3,906,390,317.84 at the end of the previous year[5] - Total liabilities decreased to CNY 2,192,395,964.52 from CNY 2,258,418,141.63, a reduction of 2.9%[36] - The company reported a total current assets of CNY 1,021,172,281.04 at the end of the period, down from CNY 1,155,073,227.12 at the beginning of the year, indicating a decrease of approximately 11.6%[30] Investment and Expenses - The company's financial expenses increased by 39.37% to ¥21,251,449.59, primarily due to interest expenses related to the Wuhan biopharmaceutical production base project[13] - Investment income showed a significant loss of -¥2,802,237.72, a decline of 1692.51% compared to a profit of ¥175,963.10 in Q1 2021[13] - Total operating costs amounted to CNY 153,986,253.73, down 4.5% from CNY 161,043,355.50[38] - Research and development expenses were CNY 21,750,925.60, a decrease of 28.8% from CNY 30,561,626.25[41] Shareholder Equity and Stock - The total equity attributable to shareholders decreased by 1.77% to ¥1,556,599,911.05 from ¥1,584,661,419.91 at the end of the previous year[5] - The total number of restricted shares at the beginning of the period was 287,730,918, with 69,214,445 shares released during the period, resulting in an ending balance of 218,516,753 restricted shares[25] - The company approved a stock incentive plan granting 14.4 million restricted shares to 205 incentive targets at a price of CNY 9.63 per share[27] Operational Highlights - The company experienced a 187.87% increase in advance receipts, amounting to ¥7,277,365.76, compared to ¥2,528,024.89 in the same period last year[9] - The company signed a binding letter of intent with Shenzhen National Infectious Disease Clinical Medical Research Center to develop a home-use rapid COVID-19 antigen test kit, with related patents currently under application[26] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[40] - The company is focusing on cost control measures to improve profitability in the upcoming quarters[40] Other Financial Metrics - The company reported a net operating profit of CNY -54,215,401.81, compared to CNY 24,445,611.03 in the previous period[41] - The company’s accounts receivable decreased to CNY 253,467,595.82 from CNY 270,977,112.96, a decline of approximately 6.5%[30] - The company’s other receivables decreased significantly from CNY 51,838,569.92 to CNY 25,936,841.28, a reduction of about 50%[30] - The company’s trading financial assets decreased to CNY 366,160,715.40 from CNY 477,675,715.02, a decline of approximately 23.3%[30] - The company’s long-term equity investments remained stable at CNY 6,008,996.58 compared to CNY 6,010,078.18 at the beginning of the year[30] Audit Status - The report for the first quarter was not audited[54]